This content is unpublished, click the edit tab and check "Published" on the bottom of the form.
19.
06.15
19:37
Close share menu
European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab), the first and only PD-1 checkpoint inhibitor approved in Europe, for both first-line and previously treated advanced melanoma patients